Abstract This article aims to present the geopolitical and public health implications of GLP-1 RAs usage in the treatment of diabetes and obesity, with recommendable strategies whereby access can be achieved equitably. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are medications which mimic the natural gut hormone GLP-1. These medications lower blood sugar, retard stomach emptying, and target the brain to enhance fullness feelings. These impacts extremely diminish appetite, culminating in pronounced weight dissipation with improved cardiac and renal health. The dual GLP-1/GIP agonist tirzepatide achieves better outcomes reaching approximately 22.5% weight decrement. In addition to weight dissipation, these agents offer significant cardiovascular advantages including 14�crement in principle severe cardiovascular events and prominent benefits in cardiac failure outcomes. The four main GLP-1 agents are Dulaglutide (Trulicity) Exenatide (Bydureon) Liraglutide (Victoza or Saxenda) Semaglutide (Ozempic or Wegovy). Public health tends to augment the well-being of diverse communities via disease surveillance, health education, preventive medicine, research, and policy development. The objective of public health is usually to promote and demonstrate wellness and prevent injury and disease as well as impede premature morbidity and mortality. The WHO guideline tends to offer directives for usage of GLP-1–based pharmacotherapies in adults having obesity, determine research and implementation lacunae. GLP-1 therapy must not substitute for obesity prevention, though. A small GLP-1 implant constitutes the recent prospect to aid patients sustain weight loss. The accessibility or availability of GLP-1 medications ought to stimulate the global community to construct an equitable, integrated, and sustainable obesity ecosystem. A vast majority of payers will cover GLP-1s for the treatment of type 2 diabetes and are elevating coverage for other FDA-approved indications, for instance, sleep and cardiovascular health. Budgets and prevention policies need to be safeguarded in accordance with the expansive spread of GLP-1 weight loss medications. The article highlights the socioeconomic factors affecting availability and access to GLP-1 therapies and the ethical invariance of not prioritizing pharmaceutical interventions beyond systemic health progress, thus, preventing medicinal monopolies and their influence on health equity. The multisectoral considerations of this work in article is pertinent, offering insights to bridge the gap between public health, pharmacognosy, pharmaceutical and geopolitics as well as the scalability of GLP-1 RAs expansive potential. In sum, this review provides a significant analysis capable of guiding future research and policy formulation, with contributions at the intersection of clinical advancement, health policy, and international public health, paving trajectories for sustainable and equitable healthcare solutions, opportunities and priorities in an increasingly interconnected global ambient. Keywords: hypothalamus, comorbidities, access, WHO, counterfeit drugs, equity. Introduction Extant GLP-1 RAs updates constitute Medicare presenting a bridge programmed permitting veritable beneficiaries’ accessibility to weight-loss medications at $50 monthly. Within drug pipeline media, the FDA gave approval for Eli Lilly’s Foundation, the initial non-peptide oral GLP-1 for obesity, whereas Novo Nordisk’s CagriSema expects FDA decision [1, 2]. Furthermore, the FDA has been targeting compounding pharmacies and telehealth platforms trafficking GLP-1 variants illegally as "generic" or FDA approval. Currently, Poison Control centers received expansive 1000% increment in phone calls concerning unintended therapeutic overdoses as these medications become extremely accessible [3] A study detected significant intracellular signaling mechanisms which are connected with the weight loss impacts of the GLP-1 medication, semaglutide. The results tend to explicate how the increasing prevalence of GLP-1s could affect human behavior, and determine newfangled opportunities and priorities for treatment improvement [4] for the future. GLP-1s effects are liable to be prolonged as the study suggests, potentially decreasing how frequently the medications are administered. cAMP modulation may constitute a trajectory to overcome obstacles faced by numerous patients. The effect of weight depreciation from the drugs is associated with elevated levels of the signaling cAMP in the postrema of the brain containing circuits correlated with appetite. In the study, increment differed from neuron to neuron, with semaglutide efficacy, the average decrement in weight from baseline was 10.2%, however, 4.9% of patients achieved an excess of 25�crement [5]. In order to address the increasing global health issues of obesity [6] affecting more than 1 billion persons, the World Health Organization (WHO) has
References CMS Launches Medicare GLP-1 Bridge, Expanding Access to GLP-1 Medications. July 1, ,2026. https://www.cms.gov/newsroom/press-releases/cms-launches-medicare-glp-1-bridge-expanding-access-glp-1-medications, Clarivate. Tracking the mid-year momentum of the 2026 Drugs to Watch. July 8, 2026. https://clarivate.com/life-sciences-healthcare/blog/tracking-the-mid-year-momentum-of-the-2026-drugs-to-watch/. Todd A. HarrisonClaudia A. Lewis Richard A. Starr. FDA’s Latest GLP 1 Crackdown: What Compounders and Telehealth Platforms Need to Know. March 13, 2026. https://www.venable.com/insights/publications/2026/03/fdas-latest-glp-1-crackdown-what-compounders. Gao, C., Geneve, I.C., Rodriguez-Gonzalez, S. et al. Semaglutide drives weight loss through cAMP-dependent mechanisms in GLP1R-expressing hindbrain neurons. Nat Metab 8, 1330–1349 (2026). https://doi.org/10.1038/s42255-026-01534-8. Su, Q.J., Ashenhurst, J.R., Xu, W. et al. Genetic predictors of GLP1 receptor agonist weight loss and side effects. Nature 653, 770–775 (2026). https://doi.org/10.1038/s41586-026-10330-z. Chukwuma Sr C. Pathophysiologic Processes, Correlates and Comorbidities of Obesity and Type 2 Diabetes Evidenced in the SARS-CoV-2/COVID-19 Pandemic. Mathews Journal of Diabetes & Obesity. 2025; 8(1). DOI: 10.30654/MJDO.10023. Francesca Celletti, MD, PhD1; Jeremy Farrar, MD, PhD2; Luz De Regil, PhD3 World Health Organization Guideline on the Use and Indications of Glucagon-Like Peptide-1 Therapies for the Treatment of Obesity in Adults. JAMA. 2026; 335;(5):434-438. doi:10.1001/jama.2025.24288. Chrysanthus Sr C.. Setting Out Advances and Trends for Safe Medications Using GLP-1/GLP Receptor, RPC Journal of Medical Sciences. RPC Publishers. 2026; 3(1). Chukwuma Sr C. Unravelling the intricacies of effective leadership, governance, and resilience within health spheres in the COVID-19 pandemic era for future guidelines, J. Modern Medical Research and Clinical Techniques. 2026; 2(3). dx.doi.org/JMMRCT/PP.0003. Chukwuma Sr C. Bioinformatics-base and determinants in the spatiotemporal variations of emerging and reemerging infectious diseases - Journal of Infectious Diseases and Preventive Medicine. Journal of Ancient Diseases & Preventive Remedies. 2018; 06(02). DOI:10.4172/2329.8731.1000182. Chukwuma Sr C. The complexity of communicable and non-communicable diseases in vulnerable populations. Advances in Bioengineering and Biomedical Science Research; ABBSR. 2020; 3(1): 5. DOI:10.33140/ABBSR.03.01.01. Kelly T, Yang W, Chen CS, Reynolds K, He J. Global burden of obesity in 2005 and projections to 2030. Int J Obes. 2008; 32(9):1431–7. WHO. WHO issues global guideline on the use of GLP-1 medicines in treating obesity. https://www.who.int/news/item/01-12-2025-who-issues-global-guideline-on-the-use-of-glp-1-medicines-in-treating-obesity. 2025. Obesity. https://www.who.int/health-topics/obesity#tab=tab_1. Naser Gharaibeh. World Health Organization (WHO) officially issues guidelines on the use of GLP-1 medications for the treatment of obesity in adults. https://www.valleyhealth.com/trending/world-health-organization-who-officially-issues-guidelines-use-glp-1-medications-treatment. Park JS, Kim KS, Choi HJ. Glucagon-Like Peptide-1 and Hypothalamic Regulation of Satiation: Cognitive and Neural Insights from Human and Animal Studies. Diabetes. 2025; 49(3): 333–347. doi: 10.4093/dmj.2025.0106. Moiz A, Filion KB, Tsoukas MA et al. Mechanisms of GLP-1 Receptor Agonist-Induced Weight Loss: A Review of Central and Peripheral Pathways in Appetite and Energy Regulation. The American Journal of Medicine. 2025; 138(6): 934-940. https://doi.org/10.1016/j.amjmed.2025.01.021. Chukwuma Sr, C. The Essence of Reflections and Perspectives of Effective Leadership and Resilience Within Health Systems During the SARS-CoV-2/COVID-19 Pandemic. Journal of Community Medicine and Health Solutions. 2026; 026–032. https://doi.org/10.29328/journal.jcmhs.1001069. Chukwuma Sr C. Interdependencies and feedback loops: Information base for the effective evaluation on how nature and anthropogenic activities shape global health and environment in ecosystem dynamics (ecodynamícs). World Journal of Pharmaceutical and Healthcare Research. 2026. Celletti F, Farrar J, De Regil L. World Health Organization Guideline on the Use and Indications of Glucagon-Like Peptide-1 Therapies for the Treatment of Obesity in Adults. JAMA. 2026; 335(5):434-438. doi: 10.1001/jama.2025.24288. Dariush Mozaffarian D, Monica Agarwal M, Alexander L et al. Nutritional priorities to support GLP-1 therapy for obesity: A joint advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and the Obesity Society. Obesity Pillars. 2025; 15(100181). https://doi.org/10.1016/j.obpill.2025.100181. Chukwuma Sr C. Is Diabetes a Model for Gene-environment Interaction in Premature Senescence? Journal of Biology, Agriculture and Healthcare. 2014; 4(25). https://www.iiste.org/Journals/index.php/JBAH/article/view/17380. Chukwuma Sr C. Trends in the Emerging Therapeutic Regimen, Alternative Remedies, Chronic Diseases, Muscle Anomalies and Functionalities of GLP-1/GLP Receptor Agonists, and Future Guideliness. RPC Journal of Medical Sciences. RPC Publishers. 2025; 2(2);DOI:https://www.doi.org/rpc/2025/rpc.jms/00450. Chukwuma Sr C. APPROACHES IN DIVERSE ISSUES OF GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS (GLP-1 RAs) IN GLOBAL HEALTH STRATEGY, ECONOMIC BURDEN, GEOPOLITICAL IMPLICATIONS AND GAIN-OF-FUNCTION RESEARCH. World Journal of Pharmaceutical and Healthcare Research. 2025; 2(11): 1-6. DOI: 10.5281/zenodo.17510578. Chukwuma Sr C. Molecular Mechanisms Which Regulate Skeletal Muscle Mass Against Obesity and The Clinicopathological Correlates. IJMCRMR. 2024. DOI: 10.61148/2994-6905/IJMCRMR/043. Chukwuma Sr C. The Persistent Incurable Prevalence and Impact of Sarcopenia, Obesity and Rare Disorders, Including Gene Expression and Drug Response Using Functional Genomics Strategies,. Biomedical Journal of Scientific & Technical Research, Biomedical Research Network. 2024; 59(1): 51125-51134. DOI: 10.26717/BJSTR.2024.59.009243. Moiz A, Filion KB, Tsoukas MA et al. The expanding role of GLP-1 receptor agonists: a narrative review of current evidence and future directions. eClinicalMedicine. 2025; 86:103363. doi: 10.1016/j.eclinm.2025.103363. Chukwuma Sr C. Perspectives for a sustainable society. Environ Manage & Hlth. 1996; 7(5):6-20. https://doi.org/10.1108/09566169610130377. Theodosios D Filippatos 1, Thalia V Panagiotopoulou 1, Moses S Elisaf. Adverse Effects of GLP-1 Receptor Agonists. Rev Diabet Stud. 2015 Feb 10;11(3):202–230. doi: 10.1900/RDS.2014.11.202. Chukwuma Sr C. Glucagon-like Peptide-1 Receptor Agonists (GLP-1RAs) are correlated with mitigation of early mortality and cardiorenal risks in Type 1 Diabetes (T1D) patients: Perspectives of the economic impact. Epidemiology and Public Health Research. 2026; 1(1). DOI: EPHR .RW. 26.001. Chukwuma Sr C.Health, risks and disease in therapeutic functionalities of Glucagon-like peptide-1 receptor agonists (GLP-1RAs) concerning human susceptibility. Greenfort International Journal of Applied Medical Science. 2025; 3(5):240-254. DOI:10.62046/gijams.2025.v03i05.002. Pearson SD, Whaley CM and Emond SK. Affordable access to GLP-1 obesity medications: strategies to guide market action and policy solutions. ICER: Institute for Clinical and Economic Review. 2025. https://icer.org/wp-content/uploads/2025/04/Affordable-Access-to-GLP-1-Obesity-Medications-_-ICER-White-Paper-_-04.09. Izham M and Ibrahim M. Geopolitical Conflicts as Emerging Determinants of Access to Medicines in Low- and Middle-Income Countries. JONUNS. 2026. https://jonuns.com/index.php/journal/article/view/1942. DOI https://doi.org/10.55463/issn.1674-2974.53.7.4. Panwar M. The Role of GLP-1 Receptor Agonists (e.g., Ozempic) in Decreasing Disparities in Diabetes and Obesity Care: A Systematic Review of Efficacy, Access, and Public Health Equity Implications,. Journal of the National Medical Association. 2025; 117(1): 6, Supplement 1. https://doi.org/10.1016/j.jnma.2025.08.017. Chukwuma Sr C. The Challenges, Issues and Opportunities of Glp-1/Glp Receptor Agonists in Research and Patient Care. J Cur Tre Clin Case Rep. 2025; 6(3): 1-12. CMS.gov. BALANCE (Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth) Model. https://www.cms.gov/priorities/innovation/innovation-models/balance. Miller J, Miller R, Varney SM, Han D. National Poison Center Trends in GLP-1 Receptor Agonist Exposures Following FDA Approval for Weight Loss. J Med Toxicol. 2026; 22(2):275–285. doi: 10.1007/s13181-026-01121-z. Witters D. In U.S., GLP-1 Usage Reaches New High - Gallup News. 7 Jul 2026. https://news.gallup.com/poll/712157/glp-usage-reaches-new-high.aspx. Chukwuma Sr C. Convergence on the constraints and challenges in the awareness, prevention, treatment and control of type 2 diabetes and related conditions. GJMR. 2018; 17(3): version 1.0. https://www.medicalresearchjournal.org/index.php/GJMR/article/view/1415. Chukwuma Sr C. The Invariant Dynamics and Consequences of Nonferrous Metal Mining Operations on Health, Environment, Economy, and Geopolitics. Greenfort International Journal of Applied Medical Science. 2026; 4(3). ISSN 3048-6904(P) ISSN 2584-2420(E). Wharton S, Lau DCW, Vallis M, Sharma AM, Biertho L et al. Obesity in adults: a clinical practice guideline. Can Med Assoc J. 2020; 192(31):E875–91. Chukwuma Sr C. Glucagon-like Peptide-1 Receptor Agonists (GLP-1RAs) Correlated With Mitigated Risks of Early Mortality, Cardiovascular and Renal Risks in Type 1 Diabetes (T1D) Subjects: Perspectives on the Economic Impact. Medico Research Chronicles. 2026; 13(3): 435-446. DOI: 10.26838/MEDRECH.2026.13.2.917.